Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Monday, October 11, 2010 - 05:30 in Health & Medicine

For patients with advanced lung cancer whose tumours carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting...

Read the whole article on

More from

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net